AbbVie Inc.
ABBV
$245.67
$1.870.77%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 64.39B | 62.82B | 61.16B | 59.64B | 58.33B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.39B | 62.82B | 61.16B | 59.64B | 58.33B |
| Cost of Revenue | 17.52B | 17.57B | 17.36B | 17.02B | 16.77B |
| Gross Profit | 46.87B | 45.25B | 43.80B | 42.62B | 41.56B |
| SG&A Expenses | 14.29B | 13.92B | 13.64B | 13.51B | 14.13B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 0.00 | -24.00M | -24.00M | -31.00M | -31.00M |
| Total Operating Expenses | 41.49B | 40.94B | 40.05B | 39.29B | 39.43B |
| Operating Income | 22.89B | 21.88B | 21.12B | 20.36B | 18.89B |
| Income Before Tax | 8.70B | 5.98B | 6.60B | 1.66B | 3.03B |
| Income Tax Expenses | 2.38B | 2.33B | 2.36B | -735.00M | -741.00M |
| Earnings from Continuing Operations | 6.32K | 3.64K | 4.23K | 2.40K | 3.77K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -6.00M | -6.00M | -7.00M | -7.00M | -8.00M |
| Net Income | 6.31B | 3.64B | 4.23B | 2.39B | 3.76B |
| EBIT | 22.89B | 21.88B | 21.12B | 20.36B | 18.89B |
| EBITDA | 30.76B | 29.92B | 29.25B | 28.61B | 27.16B |
| EPS Basic | 3.54 | 2.03 | 2.36 | 1.33 | 2.11 |
| Normalized Basic EPS | 7.23 | 6.92 | 6.65 | 6.38 | 5.89 |
| EPS Diluted | 3.54 | 2.03 | 2.36 | 1.32 | 2.10 |
| Normalized Diluted EPS | 7.22 | 6.91 | 6.64 | 6.37 | 5.88 |
| Average Basic Shares Outstanding | 7.08B | 7.08B | 7.08B | 7.07B | 7.07B |
| Average Diluted Shares Outstanding | 7.09B | 7.09B | 7.09B | 7.08B | 7.08B |
| Dividend Per Share | 6.83 | 6.74 | 6.65 | 6.56 | 6.47 |
| Payout Ratio | 189.83% | 325.12% | 275.84% | 481.49% | 301.30% |